GLP-1 Agonist Liraglutide Reduces Vascular Calcification in Both Diabetic and Non-Diabetic Rats
Liraglutide reduced vascular calcification in both diabetic and normoglycemic rat models, demonstrating a direct vascular protective effect independent of blood sugar control.
Quick Facts
What This Study Found
Liraglutide ameliorated vascular calcification in both normoglycemic and diabetic rat models, demonstrating direct vascular protection independent of glycemic control.
Key Numbers
Young rats were 3–4 months old, compared to aged rats. Specific calcification measurements and pathway expression levels were analyzed but not fully detailed in the available abstract.
How They Did This
Vascular calcification models in both normoglycemic and diabetic rats. Treated with liraglutide. Assessed vascular calcium content, vessel function, and calcification markers.
Why This Research Matters
Vascular calcification has no treatment. Showing that liraglutide directly protects blood vessels — even without diabetes — suggests GLP-1 drugs could be used to treat or prevent vascular calcification in any patient.
The Bigger Picture
Vascular calcification contributes to cardiovascular events in millions of people, including those with chronic kidney disease. Demonstrating that GLP-1 drugs work against calcification regardless of diabetes status dramatically expands their potential cardiovascular applications.
What This Study Doesn't Tell Us
Rat model. Human vascular calcification involves different pathologies (atherosclerotic vs medial). Optimal dosing for anti-calcification effect not established.
Questions This Raises
- ?Could liraglutide prevent vascular calcification in chronic kidney disease patients?
- ?What mechanism explains the direct anti-calcification effect independent of glucose control?
- ?Should non-diabetic patients at high cardiovascular risk receive GLP-1 drugs for vascular protection?
Trust & Context
- Key Stat:
- Works without diabetes Liraglutide reduced vascular calcification even in non-diabetic rats, proving direct vascular protection beyond glucose control
- Evidence Grade:
- Preliminary evidence: dual-model rat study (diabetic + normoglycemic) demonstrating direct vascular protection. No human data.
- Study Age:
- Published in 2025. Significant finding for expanding GLP-1 drug indications beyond metabolic disease.
- Original Title:
- Ameliorative effect of GLP1 agonist on vascular calcification in normoglycemic aged rat aorta via miR34a/SIRT6/NRF2/HO-1 signalling pathway.
- Published In:
- European journal of pharmacology, 1001, 177741 (2025)
- Authors:
- Abdelfattah, Amira Mohammed, Abdelnour, Hanim M, Askar, Eman M, Abdelhamid, Amira Mohamed, Elgarhi, Reham I
- Database ID:
- RPEP-09735
Evidence Hierarchy
Frequently Asked Questions
Can GLP-1 drugs protect blood vessels?
This study shows liraglutide directly reduced blood vessel calcification — even in rats without diabetes. This suggests GLP-1 drugs have vascular protective properties beyond their blood sugar effects, potentially benefiting anyone at risk for cardiovascular disease.
What is vascular calcification?
Vascular calcification is the buildup of calcium in blood vessel walls, making them stiff and less able to function. It is a major risk factor for heart attack and stroke, and currently has no approved drug treatment.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09735APA
Abdelfattah, Amira Mohammed; Abdelnour, Hanim M; Askar, Eman M; Abdelhamid, Amira Mohamed; Elgarhi, Reham I. (2025). Ameliorative effect of GLP1 agonist on vascular calcification in normoglycemic aged rat aorta via miR34a/SIRT6/NRF2/HO-1 signalling pathway.. European journal of pharmacology, 1001, 177741. https://doi.org/10.1016/j.ejphar.2025.177741
MLA
Abdelfattah, Amira Mohammed, et al. "Ameliorative effect of GLP1 agonist on vascular calcification in normoglycemic aged rat aorta via miR34a/SIRT6/NRF2/HO-1 signalling pathway.." European journal of pharmacology, 2025. https://doi.org/10.1016/j.ejphar.2025.177741
RethinkPeptides
RethinkPeptides Research Database. "Ameliorative effect of GLP1 agonist on vascular calcificatio..." RPEP-09735. Retrieved from https://rethinkpeptides.com/research/abdelfattah-2025-ameliorative-effect-of-glp1
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.